Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Radiopharmaceuticals × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 6 Everolimus 6 lanreotide 5 Temozolomide 5 anlotinib 4 Dexmedetomidine 4 surufatinib 3 Thyrotropin Alfa 3 Saline Solution 3 Injections 3 Cisplatin 3 Blood Specimen Collection 3 sintilimab 2 penpulimab 2 cabozantinib 2 Surgical Procedures, Operative 2 Sorafenib 2 Sodium Chloride 2 Rosiglitazone 2 Radiotherapy 2 Positron Emission Tomography Computed Tomography 2 Paclitaxel 2 Nivolumab 2 Metformin 2 Magnetic Resonance Spectroscopy 2 Lymph Node Excision 2 Liquid Biopsy 2 Fluorodeoxyglucose F18 2 Capecitabine 2 Biopsy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02236910 2024-10-15

Lu-DOTA-TATE

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 2 Unknown

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡